Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients

Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients

Abstract Background JS001, a humanized IgG4 monoclonal antibody against the programmed death-1 (PD-1) receptor, blocks the interaction of PD-1 with its ligands and promotes T cell activation in preclinical studies. This phase I study is designed to evaluate the safety, tolerability, and clinical act...

Full description

Bibliographic Details
Main Authors: Bixia Tang, Xieqiao Yan, Xinan Sheng, Lu Si, Chuanliang Cui, Yan Kong, Lili Mao, Bin Lian, Xue Bai, Xuan Wang, Siming Li, Li Zhou, Jiayi Yu, Jie Dai, Kai Wang, Jinwei Hu, Lihou Dong, Haifeng Song, Hai Wu, Hui Feng, Sheng Yao, Zhihong Chi, Jun Guo
Format: Article
Language:English
Published: BMC 2019-01-01
Series:Journal of Hematology & Oncology
Subjects:
PD-1
Monoclonal antibody
JS001
Melanoma
Urothelial cancer
Renal cell carcinoma
Online Access:http://link.springer.com/article/10.1186/s13045-018-0693-2

Internet

http://link.springer.com/article/10.1186/s13045-018-0693-2

Similar Items